Viking Therapeutics completes enrollment in Phase 3 VANQUISH-2 trial of VK2735; 78-week study targets about 1,000 adults with obesity and type 2 diabetes

Reuters03-26

<a href="https://laohu8.com/S/VKTX">Viking</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> completes enrollment in Phase 3 VANQUISH-2 trial of VK2735; 78-week study targets about 1,000 adults with obesity and type 2 diabetes

Viking completed patient enrollment in the Phase 3 VANQUISH-2 trial evaluating once-weekly subcutaneous VK2735 in adults with obesity and type 2 diabetes.
The randomized, double-blind, placebo-controlled study enrolled about 1,000 participants and will treat patients for 78 weeks.
Participants were randomized to VK2735 doses of 7.5 mg, 12.5 mg, or 17.5 mg, or to placebo.
The primary endpoint is percent change in body weight versus placebo at 78 weeks, with secondary measures including the share of patients achieving at least 5% weight loss.
Results from a separate Phase 1 study of maintenance dosing regimens are planned for presentation in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603260705PR_NEWS_USPR_____LA19858) on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622851962?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622851962","market":"fut","top_or_hot":-1,"title":"Viking Therapeutics completes enrollment in Phase 3 VANQUISH-2 trial of VK2735; 78-week study targets about 1,000 adults with obesity and type 2 diabetes","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> completes enrollment in Phase 3 VANQUISH-2 trial of VK2735; 78-week study targets about 1,000 adults with obesity and type 2 diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Viking completed patient enrollment in the Phase 3 VANQUISH-2 trial evaluating once-weekly subcutaneous VK2735 in adults with obesity and type 2 diabetes.\n        </li>\n<li>\n          The randomized, double-blind, placebo-controlled study enrolled about 1,000 participants and will treat patients for 78 weeks.\n        </li>\n<li>\n          Participants were randomized to VK2735 doses of 7.5 mg, 12.5 mg, or 17.5 mg, or to placebo.\n        </li>\n<li>\n          The primary endpoint is percent change in body weight versus placebo at 78 weeks, with secondary measures including the share of patients achieving at least 5% weight loss.\n        </li>\n<li>\n          Results from a separate Phase 1 study of maintenance dosing regimens are planned for presentation in Q3 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603260705PR_NEWS_USPR_____LA19858) on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viking Therapeutics completes enrollment in Phase 3 VANQUISH-2 trial of VK2735; 78-week study targets about 1,000 adults with obesity and type 2 diabetes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViking Therapeutics completes enrollment in Phase 3 VANQUISH-2 trial of VK2735; 78-week study targets about 1,000 adults with obesity and type 2 diabetes\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 19:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VKTX\">Viking</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> completes enrollment in Phase 3 VANQUISH-2 trial of VK2735; 78-week study targets about 1,000 adults with obesity and type 2 diabetes\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Viking completed patient enrollment in the Phase 3 VANQUISH-2 trial evaluating once-weekly subcutaneous VK2735 in adults with obesity and type 2 diabetes.\n        </li>\n<li>\n          The randomized, double-blind, placebo-controlled study enrolled about 1,000 participants and will treat patients for 78 weeks.\n        </li>\n<li>\n          Participants were randomized to VK2735 doses of 7.5 mg, 12.5 mg, or 17.5 mg, or to placebo.\n        </li>\n<li>\n          The primary endpoint is percent change in body weight versus placebo at 78 weeks, with secondary measures including the share of patients achieving at least 5% weight loss.\n        </li>\n<li>\n          Results from a separate Phase 1 study of maintenance dosing regimens are planned for presentation in Q3 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603260705PR_NEWS_USPR_____LA19858) on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDLbRJ53n:1","article_id":"2622851962","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622851962","pubTimestamp":1774523125,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Viking Therapeutics completes enrollment in Phase 3 VANQUISH-2 trial of VK2735; 78-week study targets about 1,000 adults with obesity and type 2 diabetes. Viking completed patient enrollment in the Phase 3 VANQUISH-2 trial evaluating once-weekly subcutaneous VK2735 in adults with obesity and type 2 diabetes.The randomized, double-blind, placebo-controlled study enrolled about 1,000 participants and will treat patients for 78 weeks.Participants were randomized to VK2735 doses of 7.5 mg, 12.5 mg, or 17.5 mg, or to placebo.The primary endpoint is percent change in body weight versus placebo at 78 weeks, with secondary measures including the share of patients achieving at least 5% weight loss.Results from a separate Phase 1 study of maintenance dosing regimens are planned for presentation in Q3 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4599":"减肥药","VKTX":"Viking Therapeutics, Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Viking Therapeutics完成VK2735的3期VANQUISH-2试验入组；为期78周的研究针对约1000名患有肥胖和2型糖尿病的成年人","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VKTX":0.9},"content_text":"Viking Therapeutics completes enrollment in Phase 3 VANQUISH-2 trial of VK2735; 78-week study targets about 1,000 adults with obesity and type 2 diabetes\n    \n\n\n          Viking completed patient enrollment in the Phase 3 VANQUISH-2 trial evaluating once-weekly subcutaneous VK2735 in adults with obesity and type 2 diabetes.\n        \n\n          The randomized, double-blind, placebo-controlled study enrolled about 1,000 participants and will treat patients for 78 weeks.\n        \n\n          Participants were randomized to VK2735 doses of 7.5 mg, 12.5 mg, or 17.5 mg, or to placebo.\n        \n\n          The primary endpoint is percent change in body weight versus placebo at 78 weeks, with secondary measures including the share of patients achieving at least 5% weight loss.\n        \n\n          Results from a separate Phase 1 study of maintenance dosing regimens are planned for presentation in Q3 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603260705PR_NEWS_USPR_____LA19858) on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622851962","isCrawlerRequest":true}